Drug intelligence / Profile preview

PP1

Development stage: Discontinued
Lead developer: PleoPharma
Modality: Small Molecules

Overview

PP1 is a synthetic small molecule that functions as a selective inhibitor of Src family tyrosine kinases. It is widely used in biomedical research to study the role of Src kinases and related signaling pathways. PP1 acts by binding to the ATP-binding site of these kinases, thereby inhibiting their phosphorylation activity. This compound is not approved for clinical use and is primarily utilized as a chemical probe in laboratory settings to dissect kinase-dependent cellular processes.

Other names: 4-Amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine

Targets

SFK (SRC family kinases)MAPK14 (p38 mitogen-activated protein kinase alpha)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on PP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PP1.

Explore the full profile